A volunteer who died during a trial of AstraZeneca Plc’s Covid-19 vaccine in Brazil did not take the vaccine and died from the coronavirus complications. As the information regarding the incident is not public yet, the person’s identity is still not revealed.
Anvisa, Brazil’s health authority, has informed that they have studied the volunteer’s death and has also received a partial report from an international committee which is assessing the trial’s safety.
Anvisa has also mentioned that the committee has suggested that the trial should continue as there have been no concerns about the safety of clinical trials.
AstraZeneca’s American depositary receipts fell as much as 3.3% in New York on Wednesday afternoon afterword of the person’s death but trimmed most of those losses in recent trading.
The clinical trial of the vaccine in the US has been put on hold for one month in September when a U.K. participant became ill, but later it has resumed its trials in the UK, Brazil, South Africa, and India.
However, the pause in the vaccine has forced Astra Zeneca and Oxford to disclose more information about the UK participant’s health.
Another vaccine maker, Johnson, and Johnson has also said that they are planning to pause its trials this month to investigate illness in the participant.
